An Open Label, Multicenter, Single-arm Trial to Assess Safety and Efficacy of Alteplase (Rt-PA) in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Alteplase (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 11 Oct 2017 Planned primary completion date changed from 10 Oct 2017 to 12 Oct 2017.
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2017 Planned End Date changed from 10 Oct 2017 to 30 Nov 2017.